These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 33037118)

  • 1. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
    Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
    Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
    N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
    Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JCH; Ishii H; Garassino M; de Marinis F; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Xiong H; Bajars M; Ruisi M; Barlesi F
    J Thorac Oncol; 2021 Aug; 16(8):1369-1378. PubMed ID: 33845211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
    Reck M; Barlesi F; Yang JC; Westeel V; Felip E; Özgüroğlu M; Dols MC; Sullivan R; Kowalski DM; Andric Z; Lee DH; Sezer A; Hu P; Wang X; von Heydebreck A; Jacob N; Mehr KT; Park K
    J Thorac Oncol; 2024 Feb; 19(2):297-313. PubMed ID: 37748693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
    Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
    Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
    J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
    Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
    Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
    Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
    Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
    Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.